Evogene(US:EVGN)2019-07-31 14:23Company Overview - Evogene aims to revolutionize product development in life-science markets using its Computational Predictive Biology (CPB) platform[6, 28] - The CPB platform utilizes AI and big data to predict candidates addressing product criteria early in development[13, 29] - Evogene's CPB platform is applied across various markets including Agriculture, Human Health, and Industrial Applications[19, 24] - The company has a corporate structure with subsidiaries focused on specific life-science markets, each with exclusive access to the CPB platform[23, 30] Financial Highlights - As of June 30, 2019, Evogene's cash position was approximately $46 million[31, 76] - The estimated net cash usage for 2019 is projected to be between $16 million and $18 million[76] - The company has no debt and is listed on both TASE (2007) and NASDAQ (2013)[31, 76] - In the first half of 2019, Evogene reported revenues of $540 thousand[77] - The operating loss for the first half of 2019 was $(9,372) thousand[77]